Piramal Enterprises on Wednesday said its subsidiary, Piramal Pharma, has completed the acquisition of Hemmo Pharmaceuticals.

"Piramal Pharma Ltd has completed the acquisition of Hemmo," Piramal Enterprises said in a regulatory filing.

In March this year, Piramal Pharma Ltd entered into an agreement to acquire a 100 per cent stake in Hemmo Pharmaceuticals for an upfront consideration of Rs 775 crore and earn-outs linked to the achievement of milestones.

With the addition of Hemmo's capabilities, Piramal Pharma will gain access to the growing peptide Active Pharmaceutical Ingredient (API) market and enhance its ability to offer integrated services to its customers globally, Piramal Pharma had said in a statement in March.

Shares of Piramal Enterprises were trading at Rs 2,463.05, up 0.69 percent on the BSE.

(To receive our E-paper on whatsapp daily, please click here. We permit sharing of the paper's PDF on WhatsApp and other social media platforms.)

Free Press Journal